Apotex Releases New Supply of Tamoxifen into Canadian Market
Dec 5, 2019Expedited Release Occurs Earlier Than Anticipated
December 5th, 2019, Toronto, Ontario - Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market. Additional releases are scheduled for December 2019 and January 2020.
Collaborating with Health Canada, Apotex expedited the return to market almost one month earlier than their latest projection.
“Our goal from the outset was to make the Canadian supply available as soon as possible to reduce the impact on patients,” said Jeff Watson, President & CEO, Apotex Inc. “We recognize the importance of this medication and that it can be unsettling for patients if it is in short supply. To facilitate a quicker re-entry to the market, we re-prioritized production of our portfolio, and were able to produce this faster than we normally would,” said Watson.
Indeed, Apotex had initially projected a release by the end of January and was then able to advance that deadline to December 31st, 2019. With additional pressure on the manufacturing teams, they were able to accelerate this date to an even earlier time.
“There’s no doubt that being a Canadian-based manufacturer and having a flexible supply chain were key enablers in us achieving this goal,” said Mr. Watson.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 1, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.